Enter a phrase above to search files and articles within the site.
Typically materials that are more than 5 years old will be archived
Displaying 1 - 6 of 6 results
Psoriatic Arthritis
https://www.niams.nih.gov/health-topics/psoriatic-arthritis
What is psoriatic arthritis? Psoriatic arthritis can occur in people who have psoriasis (scaly red and white skin patches). It affects the joints and areas where tissues attach to bone. The joints most often affected are: The outer joints of the fingers or toes. Wrists. Knees. Ankles. Lower back.
Rheumatoid Arthritis
https://www.niams.nih.gov/health-topics/rheumatoid-arthritis
What is rheumatoid arthritis? Rheumatoid arthritis (RA) is a chronic (long-lasting) disease that mostly affects joints, such as the wrist, hands, feet, spine, knees, and jaw. In joints, RA causes inflammation that leads to: Pain. Swelling Stiffness. Loss of function. Rheumatoid arthritis is an autoimmune disorder because the immune system attacks the healthy joint tissues. Normally, the immune system helps protect the body from infection and disease. RA may cause you to feel unusually tired, to have occasional fevers, and to have a loss of appetite. It also may cause other medical problems in the heart, lungs, blood, nerves, eyes
Marfan Syndrome
https://www.niams.nih.gov/health-topics/marfan-syndrome
What is Marfan syndrome? Marfan syndrome is a genetic disorder that affects the body’s ability to make healthy connective tissue, which supports the bones, muscles, organs, and tissues in your body. The condition can affect different areas of the body, including: Bones, ligaments, tendons, and cartilage. Organs, such as the heart and lungs. Skin.
New rheumatoid arthritis drug targets NIH-discovered protein
https://www.niams.nih.gov/newsroom/press-releases/rheumatoid-arthritis-drug-targets-protein
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
Accelerating Medicines Partnership (AMP)
https://www.niams.nih.gov/grants-funding/funded-research/accelerating-medicines
The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.